DOCSLIB.ORG

United States Patent (19) 11 Patent Number: 5,932,227 Higo Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent (19) 11 Patent Number: 5,932,227 Higo Et Al USOO5932227A United States Patent (19) 11 Patent Number: 5,932,227 Higo et al. (45) Date of Patent: Aug. 3, 1999 54). PERCUTANEOUSLY ADMINISTRABLE BASE 56) References Cited COMPOSITION AND DRUG COMPOSITION PREPARED THEREFROM U.S. PATENT DOCUMENTS 75 Inventors: Naruhito Higo; Yukio Kojima; 4,082,881 4/1978 Chen et al. ............................. 424/241 Ken-ichi Komori, all of Ibaragi, Japan 4.552,872 11/1985 Cooper et al. .......................... 514/175 5,254,348 10/1993 Hoffmann et al. ...................... 424/449 73 Assignee: Hisamitsu Pharmaceutical Co., Inc., 5,571,530 11/1996 Nakano et al. ......................... 424/448 Saga, Japan 21 Appl. No.: 08/374,603 Primary Examiner Thurman K. Page 22 PCT Filed: Jul. 23, 1993 ASSistant Examiner William E. Benston, Jr. e a? as Attorney, Agent, or Firm Wenderoth, Lind & Ponack, 86 PCT No.: PCT/JP93/01034 LLP S371 Date: Mar. 29, 1995 57 ABSTRACT S 102(e) Date: Mar. 29, 1995 A percutaneously administrable base composition which 87 PCT Pub. No.: WO94/02119 facilitates the percutaneous absorption of drugs and is remarkably reduced in the irritancy against the skin. The PCT Pub. Date: Feb. 3, 1994 composition comprises 10-60 wt.% of lower alcohol, 10-50 30 Foreign Application Priority Data wt.% of humectant, 10–70 wt.% of water, 0.1-15 wt.% of Jul. 23, 1992 JP J 4-218369 abirritant and 0.1-15 wt.% of absorption promoter. A drug Aug.ul. Z, 4, 1992 JP JapanaPail ..................................... , composition is prepared by adding to the above composition various active ingredients Such as antituSSive, expectorant, (51) Int. Cl." ....................................................... A61K 9/08 skeletal muscle relaxant, antivertiginous drug, narcotic, drug 52 U.S. Cl. ............................................. 424/401; 424/449 for the circulatory System, and So forth. 58 Field of Search ..................................... 424/448, 449, 424/241, 489, 452, 455; 514/772.4 18 Claims, No Drawings 5,932.227 1 2 PERCUTANEOUSLY ADMINISTRABLE BASE Under Such circumstances, these percutaneous adminis COMPOSITION AND DRUG COMPOSITION tration methods cannot provide Sufficient practical merits for PREPARED THEREFROM use of a drug, and are not therefore as yet Satisfactory in drug Stability for pharmaceutical purposes, as absorption and low This application is a 371 of PCT/JP 93/01034 filed Jul. 5 irritation to Skin, and manifestation of drug efficacy. 23, 1993. AS the example, tulobuterol is a B-stimulant drug having Selectively a bronchiectasis function and is known as a FIELD OF THE INVENTION therapeutic drug of bronchial asthma, chronic bronchitis, The present invention relates to a irritation percutaneously and dyspnea caused by airway obliteration disease. This is in administrable base composition which increases percutane general orally administered in the form of tablets or dry ous absorption of a drug and has a low irritation against Skin, syrup. Orally administered tulobuterol drug has the problem and a drug composition prepared therefrom. of Such adverse Side effects as palpitation, defect of circu latory System like increase in cardiac rate, headache, BACKGROUND OF THE INVENTION excitement, defect of psycho-nervous System like giddineSS and defect of gastric-intestinal disorder like Vomiting, AS conventional drug administration method, oral 15 administration, rectal administration, intracutaneous anorexia, and other troubles in the psycho-nervous System, administration, and intravenous administration are generally and vomiting, anorexia and other troubles in the gastric known. Especially oral administration is popularly adopted system. These side effects are considered to attribute to the temporary increase in the drug concentration in blood after among others. Oral administration has been defective in that oral administration. Continuity of the function is still insuf the liver is Susceptible to primary metabolism after absorp ficient in oral drug, and a paroxysm occurring frequently at tion of the drug, and a higher blood concentration of drug peep of dawn cannot Sufficiently be coped with. AS a than the necessary level is observed temporarily after oral measure to overcome these defects, therefore, there is a administration. Furthermore, many cases of gastrointestinal demand for a drug composition permitting a long endurance trouble, feeling of Vomiting, anorexia and other side effects of the tulobuterol concentration in blood through percuta are reported. 25 neous administration, and for this purpose, an external-use Recently, therefore, with a view to Solving these defects drug for percutaneously administering tulobuterol has been of oral administration, the method of percutaneous admin proposed (Japanese Patent Provisional Publication No. istration is attracting the general attention as permitting 63-10,716). The intent of the patent is to prevent temporary absorption of a drug safely and continuously. Efforts have increase in the concentration in blood after administration of been made to develop external-use drugs for this purpose, the drug by using a cream or patch as new method. For the and Some products have already been put to the market. purpose of promoting percutaneous absorption, there can be In the drugs for Such percutaneous administration, cited a method of having a composition comprising a lower however, percutaneous absorption of the drug is still on a alcohol, an alcohol having a carbon number of from 7 to 20 low level in many cases, and the object seems to be far from or an aliphatic hydrocarbon having a carbon number of from fully being achieved. 35 5 to 30, and water contain effective ingredients (Japanese More particularly, normal skin has originally a barrier Patent Provisional Publication No. 61-249,934). This pub function of preventing ingression of an eXenobiotic Sub lication discloses applicability of the composition in the stance into the body. A base alone used for ordinary percu form of ointment, plaster, lotion, adhesive tape impregnated taneous administration cannot therefore ensure Sufficient form and gel. A transdermal matrix based on a composition percutaneous absorption of effective ingredients blended 40 comprising polyisobutylene which is a Synthetic rubber and therein. It is therefore necessary to make contrivances to tulobuterol which is an effective ingredient is also proposed improve percutaneous absorption of a drug by controlling (Japanese Patent Provisional Publication No. 4-99,720). the barrier function of the horny Substance layer of skin. For However, these conventional methods and compositions this purpose, blending of a material known as percutaneous therefore cannot as yet be Sufficient in Stability of drug absorption promoter into the base is generally attempted. 45 absorption and irritation to skin, and drug pharmacological For example, there have been proposed dimethyl acetamide a effects. combined with ethyl alcohol, isopropyl alcohol or myristyl These circumstances are not limited to above-mentioned alcohol as an absorption promoter in combination with a case of tulobuterol, but are problems common to various lower alkylamide (U.S. Pat. No. 3,472,931), a combination drugs in application. of 2-pyrrolidone, an appropriate oil, and a Straight-chain 50 The present invention was developed to solve the prob fatty acid with ester of alcohol (U.S. Pat. No. 4.017,641), lems in the prior art as described above, and has an object and a combination of a lower alcohol having a carbon to provide a base composition for percutaneous number of from 7 to 20, an aliphatic hydrocarbon having a administration, which increases percutaneous absorption of carbon number of from 5 to 30, an alcohol ester of aliphatic the drug, and has a low irritation to skin of the portion of carboxylic acid having a carbon number of from 19 to 26, 55 administration, and a drug composition for percutaneous mono- or di-ether having a carbon number of from 10 to 24, administration, using the above composition, excellent in and ketone having a carbon number of from 11 to 15 with stability. water (Japanese Patent Provisional Publication No. 61-249.934). DISCLOSURE OF THE INVENTION However, these conventional absorption promoter and 60 The present invention provides a percutaneously admin absorption promoting compositions cannot as yet be con istrable base composition which comprises from 10 to 60 wt. sidered to be sufficient in safety of skin. Percutaneous % of lower alcohol, from 10 to 50 wt.% of humectant from absorption enhancer composition with low irritation to skin 10 to 70 wt.% of water, from 0.1 to 15 wt.% of abirritant, (Japanese Patent Provisional Publication No. 2-115,131) has and from 0.1 to 15 wt.% of absorption promoter. been proposed. In this case also, irritation is observed on the 65 The present invention provides also a drug composition skin of the portion of administration of a Subject particularly for percutaneous administration containing a drug blended Sensitive to alcohol. into the above-mentioned base composition. 5,932.227 3 4 More specifically, by administering a drug contained in over 50 wt.%, or over 30 wt %, tends to cause a decrease the above-mentioned base composition comprising lower in skin penetration of the drug. When the concentration of alcohol, the humectant, water, the abirritant, and the absorp humectant is under 10 wt.%, or under 20 wt.%, irritation tion promoter, the drug in efficiently absorbed, and irritation to the Subject skin is observed in the drug composition. to the administered portion is alleviated.
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 9.480,772 B2 Goto Et Al
    US0094.80772B2 (12) United States Patent (10) Patent No.: US 9.480,772 B2 Goto et al. (45) Date of Patent: Nov. 1, 2016 (54) GEL SHEET CONTAINING LIPID PEPTIDE (56) References Cited GELATOR AND POLYMERC COMPOUND U.S. PATENT DOCUMENTS (75) Inventors: Masahiro Goto, Fukuoka (JP); 5,503,776 A * 4/1996 Murase ................. A23L 3,3526 Takayuki Imoto, Funabashi (JP); 252/.397 Tsubasa Kashino, Funabashi (JP); 2003/0.165560 A1* 9, 2003 Otsuka et al. ................ 424,445 2009/0297587 A1 12/2009 Yang et al. Takehisa Iwama, Funabashi (JP); 2010/0279955 A1 * 1 1/2010 Miyachi et al. ............. 514,219 Nobuhide Miyachi, Tokyo (JP) 2010/0291210 Al 11/2010 Miyachi et al. (73) Assignees: NISSAN CHEMICAL INDUSTRIES, FOREIGN PATENT DOCUMENTS LTD., Tokyo (JP). KYUSHU EP 2 494. 953 A1 9, 2012 UNIVERSITY, Fukuoka-shi (JP) JP A-6-313.064 11, 1994 JP A-9-267453 10, 1997 (*) Notice: Subject to any disclaimer, the term of this JP B2-3107488 11 2000 patent is extended or adjusted under 35 JP A-2009-102228 5, 2009 JP A-2010-95586 4/2010 U.S.C. 154(b) by 411 days. WO WO O2/22182 A1 3, 2002 WO WO 2009/005151 A1 1, 2009 (21) Appl. No.: 13/885,099 WO WO 2009/005152 A1 1, 2009 WO WO 2010/O13555 A1 2, 2010 WO WO 2011/052613 A1 5, 2011 (22) PCT Filed: Nov. 11, 2011 OTHER PUBLICATIONS (86). PCT No.: PCT/UP2011/076109 S 371 (c)(1), Takamura et al., “Drug Release from Freeze-Thaw Poly(vinyl (2), (4) Date: Jul.
    [Show full text]
  • Gel Sheet Comprising Lipidic Peptide Type Gelling Agent and Polymeric Compound
    (19) TZZ ¥ __T (11) EP 2 638 921 A1 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 153(4) EPC (43) Date of publication: (51) Int Cl.: 18.09.2013 Bulletin 2013/38 A61L 15/16 (2006.01) A61K 8/02 (2006.01) A61K 8/34 (2006.01) A61K 8/64 (2006.01) (2006.01) (2006.01) (21) Application number: 11839325.5 A61K 8/65 A61K 8/73 A61K 8/81 (2006.01) A61K 8/86 (2006.01) (2006.01) (2006.01) (22) Date of filing: 11.11.2011 A61K 8/891 A61K 9/70 A61K 47/10 (2006.01) A61K 47/14 (2006.01) A61K 47/30 (2006.01) A61K 47/32 (2006.01) A61K 47/34 (2006.01) A61K 47/36 (2006.01) A61K 47/42 (2006.01) A61K 47/44 (2006.01) A61Q 19/00 (2006.01) (86) International application number: PCT/JP2011/076109 (87) International publication number: WO 2012/063947 (18.05.2012 Gazette 2012/20) (84) Designated Contracting States: • IMOTO, Takayuki AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Funabashi-shi GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Chiba 274-8507 (JP) PL PT RO RS SE SI SK SM TR • KASHINO, Tsubasa Funabashi-shi (30) Priority: 12.11.2010 JP 2010253736 Chiba 274-8507 (JP) • IWAMA, Takehisa (71) Applicants: Funabashi-shi • Nissan Chemical Industries, Ltd. Chiba 274-8507 (JP) Chiyoda-ku • MIYACHI, Nobuhide Tokyo 101-0054 (JP) Tokyo 101-0054 (JP) • Kyushu University Fukuoka 812-8581 (JP) (74) Representative: HOFFMANN EITLE Patent- und Rechtsanwälte (72) Inventors: Arabellastrasse 4 • GOTOH, Masahiro 81925 München (DE) Fukuoka-shi Fukuoka 812-8581 (JP) (54) GEL SHEET COMPRISING LIPIDIC PEPTIDE TYPE GELLING AGENT AND POLYMERIC COMPOUND (57) There is provided a gel sheet that has high bio- pharmaceutically usable salt of the lipid peptide; and a compatibility and safety, can contain both a hydrophilic polymeric compound, wherein the polymeric compound medicinal agent and a hydrophobic medicinal agent, and is included in an amount of more than 1% (w/w) and less provides an excellent feel in use during the application than 50% (w/w) with respect to the total mass of the gel onto human skin or others.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,846,975 Pan Et Al
    USOO5846975A United States Patent (19) 11 Patent Number: 5,846,975 Pan et al. (45) Date of Patent: Dec. 8, 1998 54 USE OF AMINO HYDROGENATED FOREIGN PATENT DOCUMENTS QUINAZOLINE COMPOUNDS AND B41-010330 6/1966 Japan. DERVATIVES THEREOF FOR ABSTAINING B44-010903 6/1966 Japan. FROM DRUG DEPENDENCE B44-010904 6/1966 Japan. B44-010906 6/1966 Japan. 75 Inventors: Xinfu Pan, Beijing; Fanglong Qiu, B42-009355 5/1967 Japan. Hunan, both of China B42-009356 5/1967 Japan. 1370905 10/1974 United Kingdom. 73 Assignee: Nanning Maple Leaf Pharmaceutical Co., Ltd., Guangxi Province, China OTHER PUBLICATIONS 21 Appl. No.: 640,781 Y. Kishi et al., J. Am. Chem. Soc., 94:26, pp. 9217-9221 (Dec. 27, 1972). 22 PCT Filed: Mar. 11, 1995 T. Goto et al., Tetrahedron, vol. 21, pp. 2059–2088 (1965). E. Murtha et al., Journal of Pharmacology and Experimen 86 PCT No.: PCT/CN95/00016 tal Therapeutics., vol. 122, pp. 247-254 (1958). S371 Date: May 21, 1996 Chemical Abstracts AN 1977: 268, Fredrikson et al., 1976. S 102(e) Date: May 21, 1996 Primary Examiner Keith D. MacMillan Attorney, Agent, or Firm-Birch, Stewart, Kolasch & Birch, 87 PCT Pub. No.: WO95/24903 LLP PCT Pub. Date: Sep. 21, 1995 57 ABSTRACT 30 Foreign Application Priority Data This invention relates to the use of amino hydrogenated quinazoline compounds and derivatives thereof, Such as Mar. 17, 1994 ICN China ............................. 941 10873.2 tetrodotoxin, for abstaining from drug dependence in (51) Int. Cl." ................................................... A61K 31/505 human. Such compounds are administered by Subcutaneous, 52 U.S.
    [Show full text]
  • Latin Derivatives Dictionary
    Dedication: 3/15/05 I dedicate this collection to my friends Orville and Evelyn Brynelson and my parents George and Marion Greenwald. I especially thank James Steckel, Barbara Zbikowski, Gustavo Betancourt, and Joshua Ellis, colleagues and computer experts extraordinaire, for their invaluable assistance. Kathy Hart, MUHS librarian, was most helpful in suggesting sources. I further thank Gaylan DuBose, Ed Long, Hugh Himwich, Susan Schearer, Gardy Warren, and Kaye Warren for their encouragement and advice. My former students and now Classics professors Daniel Curley and Anthony Hollingsworth also deserve mention for their advice, assistance, and friendship. My student Michael Kocorowski encouraged and provoked me into beginning this dictionary. Certamen players Michael Fleisch, James Ruel, Jeff Tudor, and Ryan Thom were inspirations. Sue Smith provided advice. James Radtke, James Beaudoin, Richard Hallberg, Sylvester Kreilein, and James Wilkinson assisted with words from modern foreign languages. Without the advice of these and many others this dictionary could not have been compiled. Lastly I thank all my colleagues and students at Marquette University High School who have made my teaching career a joy. Basic sources: American College Dictionary (ACD) American Heritage Dictionary of the English Language (AHD) Oxford Dictionary of English Etymology (ODEE) Oxford English Dictionary (OCD) Webster’s International Dictionary (eds. 2, 3) (W2, W3) Liddell and Scott (LS) Lewis and Short (LS) Oxford Latin Dictionary (OLD) Schaffer: Greek Derivative Dictionary, Latin Derivative Dictionary In addition many other sources were consulted; numerous etymology texts and readers were helpful. Zeno’s Word Frequency guide assisted in determining the relative importance of words. However, all judgments (and errors) are finally mine.
    [Show full text]
  • An Access-Dictionary of Internationalist High Tech Latinate English
    An Access-Dictionary of Internationalist High Tech Latinate English Excerpted from Word Power, Public Speaking Confidence, and Dictionary-Based Learning, Copyright © 2007 by Robert Oliphant, columnist, Education News Author of The Latin-Old English Glossary in British Museum MS 3376 (Mouton, 1966) and A Piano for Mrs. Cimino (Prentice Hall, 1980) INTRODUCTION Strictly speaking, this is simply a list of technical terms: 30,680 of them presented in an alphabetical sequence of 52 professional subject fields ranging from Aeronautics to Zoology. Practically considered, though, every item on the list can be quickly accessed in the Random House Webster’s Unabridged Dictionary (RHU), updated second edition of 2007, or in its CD – ROM WordGenius® version. So what’s here is actually an in-depth learning tool for mastering the basic vocabularies of what today can fairly be called American-Pronunciation Internationalist High Tech Latinate English. Dictionary authority. This list, by virtue of its dictionary link, has far more authority than a conventional professional-subject glossary, even the one offered online by the University of Maryland Medical Center. American dictionaries, after all, have always assigned their technical terms to professional experts in specific fields, identified those experts in print, and in effect held them responsible for the accuracy and comprehensiveness of each entry. Even more important, the entries themselves offer learners a complete sketch of each target word (headword). Memorization. For professionals, memorization is a basic career requirement. Any physician will tell you how much of it is called for in medical school and how hard it is, thanks to thousands of strange, exotic shapes like <myocardium> that have to be taken apart in the mind and reassembled like pieces of an unpronounceable jigsaw puzzle.
    [Show full text]
  • The Use of Amino Hydrogenated Quinazoline Compounds and Derivatives Thereof for Abstaining from Drug Dependence
    * — mi ii ii ii ii mi mi urn ii i ii OJII Eur°Pean Patent Office <*S Office europeen des brevets (11) EP 0 750 909 A1 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 158(3) EPC (43) Date of publication: (51) |nt. CI.6: A61 K 31/505, A61 K 31/495 02.01.1997 Bulletin 1997/01 (86) International application number: (21 ) Application number: 9591 1 187.3 PCT/CN95/0001 6 (22) Date of filing: 11.03.1995 (87) International publication number: WO 95/24903 (21.09.1995 Gazette 1995/40) (84) Designated Contracting States: (72) Inventors: BE DE FR GB • PAN, Xinfu C-1205 New Building 4 (30) Priority: 17.03.1994 CN 94110873 Beijing 100022 (CN) • QIU, Fanglong (71 ) Applicant: NANNING MAPLE LEAF Room 8_4 Gongnongqiaocun 21 PHARMACEUTICAL CO., LTD. Hunan 41 0007 (CN) Nanning, Guangxi Zhuang Autonomous Region 530022 (74) Representative: TER MEER - MULLER - (CN) STEINMEISTER & PARTNER Mauerkircherstrasse 45 81679 Munchen (DE) (54) THE USE OF AMINO HYDROGENATED QUINAZOLINE COMPOUNDS AND DERIVATIVES THEREOF FOR ABSTAINING FROM DRUG DEPENDENCE (57) This invention relates to the use of amino hydrogenated quinazoline compounds and derivatives thereof, such as tetrodotoxin, for abstaining from drug dependence in human. Such compounds are adminis- tered by subcutaneous, intramuscular or intravenous injection for abstaining from drug dependence, the said drug is alkaloids and nitrogen-containing non-amino acid compound, for example opium, morphine, heroin and the like. Such compounds without drug depend- ence and with low toxicity and side effect can abstain rapidly from drug dependence. < O <7> O o Q_ LU Printed by Rank Xerox (UK) Business Services 2.13.11/3.4 EP 0 750 909 A1 Description TECHNICAL FIELD This invention is concerned to amino hydrogenated quinazoline compounds and derivatives thereof, particularly their new application for abstaining human's from drug dependence on alkaloids and synthetic non-amino acid nitrogen.
    [Show full text]
  • Epsydict Book – English Edition Aberration 4
    ENGLISH DICTIONARY OF PSYCHOLOGICAL SCIENCES English – French – Arabic Jamel TURKY í{{{{{ée†ÃÖ]<í{{{éŠËßÖ]<Ýç{{{×ÃÖ]<í{{{Óf<l]…]‚{{{‘c DICTIONARY OF PSYCHOLOGICAL SCIENCES English – French – Arabic 3 A Ab ﺷﺎرد اﻟﻔﻜﺮ، ﺧﺒﻞ اﻟﻔﻜﺮ Abalienated abalieneté ﺧﺒﻞ، ﺷﺮود اﻟﻔﻜﺮ Abalienation abalienation ﲣﻠّﻲ، هﺠﺮان، ﺗﺮك، إﳘﺎل Abandon abandon ﺣﺼﺮ اﳍﺠﺮان Abandon anguish angoisse d'abandon ﻗﻠﻖ اﳍﺠﺮ Abandon anxiety anxiété d’abandon إﺣﺴﺎس ﺑﺎﳍﺠﺮان Abandon sense sentiment d’abandon وﺿﻌﻴّﺔ هﺠﺮان Abandon situation situation d'abandon ﻣﻬﻤﻞ، ﻣﱰوك Abandoned abandonné ﻃﻔﻮﻟﺔ ﻣﻬﻤﻠﺔ Abandoned infancy enfance abandonnée إﳘﺎﱄ Abandonic abandonnique هﺠﺮ، ﺗﺮك، إﳘﺎل، ﲣﻠّﻲ Abandonment abandon ﲣﻠّﻲ ﻋﻦ اﻟﺬّات Abandonment (self-) abandon de soi ﻋﻘﺪة اﳍﺠﺮان Abandonment complex complexe d’abandon ﻋﺼﺎب اﳍﺠﺮ Abandonment neurosis névrose d'abandon اﺳﺘﺠﺎﺑﺔ اﳍﺠﺮ Abandonment reaction réaction d'abandon ﲥﺪﻳﺪ ﺑﺎﳍﺠﺮ Abandonment treat menace d'abandon ﻋﻤﻪ اﻟﻮزن Abarognosis abarognosie ﲢﻘﲑ، ﺳﻔﺎﻟﺔ، ﺧﻔﺾ، ﺗﻨﻜﻴﺲ Abasement dévalorisation ﲢﻘﲑ اﻟﺬّات Abasement (self-) auto-dévalorisation ﻻﺧﻄﻮ، ﻻﺧﻄﻮﻳّﺔ Abasia abasie ﻻﺧﻄﻮﻳّﺔ رﻗﺼﻴّﺔ Abasia (choreic-) abasie choréique ﻻﺧﻄﻮﻳّﺔ ﺷﻠﻠﻴّﺔ Abasia (paralytic-) abasie paralytique ﻻﺧﻄﻮﻳﺔ ﺗﺸﻨّﺠﻴّﺔ Abasia (spastic-) abasie spastique ﻻﺧﻄﻮ-ﻻوﻗﻮف Abasia-astasia astasie-abasie ﻻﺧﻄﻮ رﳓﻲ، ﺧﻄﺮان Abasia atactica abasie atactique ﻻﺧﻄﻮي، ﻣﺘﻐﻴّﻒ Abasic abasique ﺿﻮر، رهﻖ، ﺗﺒﻠّﺪ Abatement abattement, effondrement ﺗﺒﻠّﺪ اﻟﺬّهﻦ Abatement (psychic-) ralentissement psychique ﻻﺧﻄﻮي Abatic abatique ﺑﻄﲏ Abdominal abdominal ﺻﺮع ﺑﻄﲏ Abdominal epilepsy épilepsie abdominale ﺳﻮداوﻳّﺔ
    [Show full text]
  • Abampere (Ab-AM-Peer)—The Cgs Electromagnetic Unit of Electric Current Equivalent to 10 Amperes
    HEAVA1p.qxd 7/16/1 9:59 AM Page 1 A AA B abampere (ab-AM-peer)—the cgs electromagnetic unit of electric current equivalent to 10 amperes. abdomen (AB-duh-men)—the belly; the cavity in the body between the thorax and the pelvis that contains the stomach, intestines, liver, and kidneys. abducent (ab-DOOS-int)—drawing away from, as muscles draw away. abducent nerve (ab-DOOS-int NURV)—either of the six cranial nerves; small motor nerves supplying the external rectus muscle of the eye. abductor (ab-DUK-tur)—muscles that separate the fingers. Opposite of adductor. abductor hallucis (ab-DUK-tor huh-LOO-sis)—a muscle of the great toe. ability (uh-BIL-ih-tee)—the quality or state of being able to perform. abiogenesis (ay-by-oh-JEN-uh-sus)—the generating or springing up of living from nonliving matter; spontaneous generation. abiosis (ab-ee-OH-sis)—absence of life. abirritant (ab-IHR-uh-tant)—a soothing agent that relieves irritation. abnormal (ab-NOR-mul)—irregular; contrary to the natural law or customary order. abnormality (ab-nor-MAL-ih-tee)—the state or condition of being ab- normal or unusual. abohm (ab-OHM)—the cgs electromagnetic unit of resistance equal to one millionth of an ohm. aboral (ah-BOHR-ul)—located or situated opposite to or away from the mouth. abrade (uh-BRAYD)—to remove or roughen by friction or rubbing. 1 HEAVA1p.qxd 7/16/1 9:59 AM Page 2 2 abrasion abrasion (uh-BRAY-zhun)—scraping of the skin; excoriation; rubbing A or wearing off of the surface; an irritation; a scraped or B scratched area of the skin.
    [Show full text]
  • Jay Yasgur Homeopathic Dictionary and Holistic Health Reference Reading Excerpt Homeopathic Dictionary and Holistic Health Reference of Jay Yasgur Publisher: Yasgur
    Jay Yasgur Homeopathic Dictionary and Holistic Health Reference Reading excerpt Homeopathic Dictionary and Holistic Health Reference of Jay Yasgur Publisher: Yasgur http://www.narayana-verlag.com/b2280 In the Narayana webshop you can find all english books on homeopathy, alternative medicine and a healthy life. Copying excerpts is not permitted. Narayana Verlag GmbH, Blumenplatz 2, D-79400 Kandern, Germany Tel. +49 7626 9749 700 Email [email protected] http://www.narayana-verlag.com CONTENTS Acknowledgements ................................................................... ii Foreword..................................................................................iii Preface...................................................................................... iv What Is Homeopathy?..............................................................vii Scientific Terminology as It Relates to Homeopathy .................ix Prefixes ...............................................................................ix Suffixes............................................................................... xi Compound Words and Eponyms ......................................xii Onomatopoetic Words and Diphthongs..........................xiii Homeopathic Organizations and Pharmacies ..........................xiv Homeopathic Dictionary .......................................................... 1 Birth Charts of S.C.F. Hahnemann ........................................286 Anatomical Regions ...............................................................288
    [Show full text]
  • Design, Synthesis, and Evaluation of Aryl Hydantoins and Ureas As Antischistosomal Agents
    University of Nebraska Medical Center DigitalCommons@UNMC Theses & Dissertations Graduate Studies Fall 12-16-2016 Design, Synthesis, and Evaluation of Aryl Hydantoins and Ureas as Antischistosomal Agents Chunkai Wang University of Nebraska Medical Center Follow this and additional works at: https://digitalcommons.unmc.edu/etd Part of the Medicinal and Pharmaceutical Chemistry Commons Recommended Citation Wang, Chunkai, "Design, Synthesis, and Evaluation of Aryl Hydantoins and Ureas as Antischistosomal Agents" (2016). Theses & Dissertations. 157. https://digitalcommons.unmc.edu/etd/157 This Dissertation is brought to you for free and open access by the Graduate Studies at DigitalCommons@UNMC. It has been accepted for inclusion in Theses & Dissertations by an authorized administrator of DigitalCommons@UNMC. For more information, please contact [email protected]. DESIGN, SYNTHESIS, AND EVALUATION OF ARYL HYDANTOINS AND UREAS AS ANTISCHISTOSOMAL AGENTS BY Chunkai Wang Design, synthesis, and evaluation of aryl hydantoins and ureas as antischistosomal agents by Chunkai Wang A DISSERTATION Presented to the Faculty of the University of Nebraska Graduate College in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy Pharmaceutical Sciences Graduate Program Under the Supervision of Professor Yuxiang Dong University of Nebraska Medical Center Omaha, Nebraska October, 2016 Supervisory Committee: Yuxiang Dong, Ph.D. Jonathan L. Vennerstrom, Ph.D. Joseph Vetro, Ph.D. Jialin Zheng, M.D. i ACKNOWLEDGMENTS I would like to express my sincere and deep gratitude to my academic advisor Dr. Yuxiang Dong and the big boss Dr. Jonathan L Vennerstrom for their guidance, mentorship, encouragements and discussions. I would also like to thank the committee members, Dr.
    [Show full text]
  • Medicinal Plants and Drugs
    MEDICINAL PLANTS AND DRUGS Created by XMLmind XSL-FO Converter. MEDICINAL PLANTS AND DRUGS Created by XMLmind XSL-FO Converter. Table of Contents 1. Medicinal Plants and Drugs ............................................................................................................ 1 1. Introduction ........................................................................................................................... 1 2. Part I. General information ................................................................................................... 2 2.1. 1. The History of Herbal Medicine ........................................................................... 2 2.2. 2. The History of Hungarian Herbal Medicine ......................................................... 4 2.3. 3. The definition of medicinal plants. ....................................................................... 5 2.4. 4. The definition and nomenclature of drugs ............................................................ 6 2.4.1. Test questions .............................................................................................. 7 2.5. 5. Can herbs be carcinogenic (cause cancer)? ........................................................ 10 2.6. 6. Active ingredients ............................................................................................... 10 2.7. 7. The function of active ingredients in the vegetable kingdom ............................. 13 2.8. 8. Factors affecting the production of active ingredients .......................................
    [Show full text]
  • Masterarbeit / Master's Thesis
    , MASTERARBEIT / MASTER’S THESIS Titel der Masterarbeit / Title of the Master‘s Thesis Digenean trematodes in freshwater snails in the surroundings of Vienna with a focus on species involved in human infections verfasst von / submitted by Nadine Hohensee BSc angestrebter akademischer Grad / in partial fulfilment of the requirements for the degree of Master of Science (MSc) Wien, 2016 / Vienna 2016 Studienkennzahl lt. Studienblatt / A 066 834 degree programme code as it appears on the student record sheet: Studienrichtung lt. Studienblatt / Masterstudium Molekulare Biologie degree programme as it appears on the student record sheet: Betreut von / Supervisor: Assoz. Prof. Univ.-Doz. Mag. Julia Walochnik, PhD Statutory Declaration I declare that I have authored this thesis independently, that I have not used other than the declared sources / resources and that I have explicitly marked all mate- rial which has been quoted either literally or by content from the used sources. …………………………… ……………………………………………….. Date Signature Index Index 1. Introduction ...................................................................................................................................... 1 1.1. Digenean Trematodes ....................................................................................................................... 1 1.1.1. Classification ............................................................................................................................... 1 1.1.2. Geographical Distribution .........................................................................................................
    [Show full text]